Revenue Showdown: Taro Pharmaceutical Industries Ltd. vs Travere Therapeutics, Inc.

Pharma Revenue Trends: Taro vs. Travere

__timestampTaro Pharmaceutical Industries Ltd.Travere Therapeutics, Inc.
Wednesday, January 1, 201475928500028203205
Thursday, January 1, 201586294400099892000
Friday, January 1, 2016950751000133591000
Sunday, January 1, 2017879387000154937000
Monday, January 1, 2018661913000164246000
Tuesday, January 1, 2019669893000175338000
Wednesday, January 1, 2020644769000198321000
Friday, January 1, 2021548970000227490000
Saturday, January 1, 2022561347000212018000
Sunday, January 1, 2023572952000145238000
Monday, January 1, 2024629182000
Loading chart...

Unlocking the unknown

Revenue Showdown: A Tale of Two Pharmaceutical Giants

In the competitive world of pharmaceuticals, Taro Pharmaceutical Industries Ltd. and Travere Therapeutics, Inc. have been on distinct revenue trajectories over the past decade. Taro, a stalwart in the industry, saw its revenue peak in 2016, with a notable 25% increase from 2014. However, the subsequent years witnessed a decline, with 2023 revenues dropping by approximately 40% from their peak. In contrast, Travere Therapeutics, a rising star, experienced a remarkable growth spurt, with revenues increasing nearly eightfold from 2014 to 2021. Despite this impressive growth, Travere's revenue saw a dip in 2023, highlighting the volatility in the biotech sector. The data for 2024 remains incomplete, leaving room for speculation on future trends. This revenue showdown underscores the dynamic nature of the pharmaceutical industry, where market forces and innovation drive financial outcomes.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025